Clinical trials: Dyspepsia
Functional Dyspepsia
Probiotic and Ginger Supplement for Symptoms and Quality of Life in Functional Dyspepsia (SUBTILE)
Functional dyspepsia (FD) is a frequent functional gastrointestinal disorder characterized by bothersome postprandial fullness, early satiety, epigastric pain, or burning, in the absence of any structural or metabolic cause.
- Trial name
- SUBTILE (NCT07212907)
- Testing
- Symbiosys® Stomalex (commercial name)
- Where
- France
- Volunteers
- 198 people
- Sponsor
- Biocodex
Constipation, Dyspepsia
Study of Yili "Changqing" Pro-ABB Yoghurt in the Improvement of Human Gastrointestinal Tract System
The purpose of this study is to determine whether Yili "Chang Qing" Pro-ABB yoghurt is effective in improving mild constipation and the intestinal micro-ecology environment \& alimentation.
- Conditions
- Constipation, Dyspepsia, Flatulence, Abdominal Pain
- Trial name
- NCT01682798
- Testing
- Yili "Chang Qing" Pro-ABB yoghurt (Formula 1), Yili "Chang Qing" Pro-ABB yoghurt (Formula 2)
- Where
- 2 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting
This is an observational study in which data from people with functional gastrointestinal disorders who decide on their own or by recommendation of their doctors or pharmacists to take Iberogast Advance are collected and studied.
- Conditions
- Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome, Functional Dyspepsia
- Trial name
- NCT05389709
- Testing
- Iberogast (STW5-II, BAY98-7410)
- Where
- Germany
- Volunteers
- 184 people
- Sponsor
- Bayer
Functional Dyspepsia
A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia
The purpose of this study is to evaluate pharmacokinetics, efficacy and safety of Z-338 of pediatric patients with functional dyspepsia (FD).
- Trial name
- NCT04526119
- Testing
- Acotiamide hydrochloride hydrate
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- Zeria Pharmaceutical
Dyspepsia
The Effects of Z-338 in Subjects With and Without Functional Dyspepsia
To assess in subjects with and without functional dyspepsia the effects of Z-338 on: 1. Type and severity of symptoms a standardized nutrient challenge 2.
- Trial name
- NCT00298194
- Testing
- Z-338
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Zeria Pharmaceutical
Biliary Dyspepsia
A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia
The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia
- Trial name
- NCT07016269
- Testing
- CnU capsule 500 mg(250mg 2 capsule)
- Where
- 8 sites in South Korea
- Volunteers
- 358 people
- Sponsor
- Myungmoon Pharma. Co. Ltd.
ECL-cell Hyperplasia, Parietal-cell Hyperplasia
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal.
- Conditions
- ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity, Dyspepsia
- Trial name
- NCT02620696
- Testing
- netazepide
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Heartburn
Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn
Remote un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in subjects with heartburn.
- Trial name
- NCT05363618
- Testing
- Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Microbiome Health Sciences
Functional Dyspepsia
A Study to Demonstrate the Efficacy and Safety of Motilitone®
This is a phase IV , comparative study to evaluate the efficacy and safety of Motiltone® in treatment of the patients with functional dyspepsia.
- Trial name
- NCT01817465
- Testing
- Motilitone ®, Pantoline®, Motilitone® and Pantoline®
- Where
- South Korea
- Volunteers
- 389 people
- Sponsor
- Dong-A ST Co., Ltd.
Functional Dyspepsia
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
This study is a multi-center, randomized, active-controlled, double-blind, non-inferiority, phase III clinical trial evaluating efficacy and safety of once-daily mosapride (UI05MSP015CT) in patients with functional dyspepsia.
- Trial name
- NCT03225248
- Testing
- UI05MSP015CT, Gasmotin
- Volunteers
- 143 people
- Sponsor
- Korea United Pharm. Inc.
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Dyspepsia
Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia.
- Trial name
- NCT00112177
- Testing
- Itopride Hydrochloride
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Forest Laboratories
Functioanl Dyspepsia
The Effect of Z-338 in Subjects With Functional Dyspepsia
Z-338; PhaseIIb, Single-centre, Randomized, Double-blind, Placebo-controlled, Parallel group study in Subjects with Functional Dyspepsia, evaluate the motility of gastro-duodenum by ultrasound
- Trial name
- NCT00458328
- Testing
- Z-338
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Zeria Pharmaceutical
Indigestion, Dyspepsia
A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux…
- Conditions
- Indigestion, Dyspepsia, Bloating, Loss of Appetite
- Trial name
- NCT06755671
- Testing
- Danning Tablet
- Where
- China
- Volunteers
- 4,500 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Dyspepsia
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
- Trial name
- NCT00232102
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 423 people
- Sponsor
- Novartis
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251992
- Testing
- Esomeprazole
- Where
- 183 sites in Austria, Belgium and 11 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Functional Dyspepsia
To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia
To Evaluate the efficacy of Z-338 in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms in order to further determine the optimal dosage and efficacy parameters for PhaseIII clinical trials.
- Trial name
- NCT00333372
- Testing
- Z-338
- Where
- Japan
- Volunteers
- 440 people
- Sponsor
- Zeria Pharmaceutical
Dyspepsia, H. Pylori Infection
Supplementation With L. Reuteri in H. Pylori Infected Adults
To determine whether simultaneous use of L. reuteri ProGastria and proton pump inhibitors can eradicate H. pylori in humans in the absence of antibiotics.
- Trial name
- NCT01449500
- Testing
- L. reuteri
- Where
- Slovakia
- Volunteers
- 56 people
- Sponsor
- Lama Medical Care s.r.o.
Functional Dyspepsia
DLBS2411 Treatment For Functional Dyspepsia
This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients…
- Trial name
- NCT05248802
- Testing
- DLBS2411
- Where
- 8 sites in Indonesia
- Volunteers
- 106 people
- Sponsor
- Dexa Medica Group
Functional Dyspepsia
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy adults.
- Trial name
- NCT00850746
- Testing
- YM443, Moxifloxacin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc